30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

BioCryst Pharmaceuticals Inc (BCRX)

Track

Over the last 90 days, BioCryst Pharmaceuticals Inc. has seen a net insider selling of $605,107.23, with a total of six transactions, all of which were sales. No executive transactions were recorded in this period. The stock price has experienced a slight decrease of 1.1% over the same 90-day timeframe.
Stock chart
Ticker: BCRX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
McKee Amy E
1 sale — total 100,285 USD
Sale 18 May 2026
Value US$330,809.65 | Price 216.39 | Shares 35,624
Proposed sale 18 May 2026
Value US$2,330,268.20 | Price 90.58 | Shares 86,543
Planned sale 13 May 2026
Value US$596,250.00 | Price 9.54 | Shares 62,500
Proposed sale 13 May 2026
Value US$596,250.00 | Price 9.54 | Shares 62,500
Sale 20 Mar 2026
Value US$504,822.63 | Price 10.11 | Shares 49,933
Proposed sale 20 Mar 2026
Value US$504,620.17 | Price 10.11 | Shares 49,933
Planned sale 16 Mar 2026
Value US$1,372,500.00 | Price 9.15 | Shares 150,000
Proposed sale 16 Mar 2026
Value US$1,372,007.37 | Price 9.15 | Shares 150,000
Proposed sale 2 Mar 2026
Value US$2,646,856.75 | Price 8.65 | Shares 305,995
Planned sale 22 Dec 2025
Value US$166,563.45 | Price 7.65 | Shares 21,773
Proposed sale 22 Dec 2025
Value US$166,563.45 | Price 7.65 | Shares 21,773
Planned sale 15 Dec 2025
Value US$162,256.50 | Price 7.65 | Shares 21,210
Proposed sale 15 Dec 2025
Value US$162,256.50 | Price 7.65 | Shares 21,210
Proposed sale 3 Dec 2025
Value US$151,240.50 | Price 7.65 | Shares 19,770
Planned sale 3 Dec 2025
Value US$151,240.50 | Price 7.65 | Shares 19,770
Sale 2 Dec 2025
Value US$367,215.52 | Price 7.21 | Shares 50,906
Proposed sale 2 Dec 2025
Value US$367,215.98 | Price 7.21 | Shares 50,906
Planned sale 1 Dec 2025
Value US$646,510.62 | Price 7.10 | Shares 91,004
Proposed sale 1 Dec 2025
Value US$644,308.32 | Price 7.08 | Shares 91,004
Proposed sale 25 Nov 2025
Value US$327,957.00 | Price 6.80 | Shares 48,229
Proposed sale 21 Nov 2025
Value US$307,685.00 | Price 7.11 | Shares 43,275
Planned sale 13 Nov 2025
Value US$68,544.00 | Price 7.14 | Shares 9,600
Proposed sale 13 Nov 2025
Value US$68,544.00 | Price 7.14 | Shares 9,600
Sale 13 Aug 2025
Value US$595,868.00 | Price 8.51 | Shares 70,000
Proposed sale 13 Aug 2025
Value US$595,870.74 | Price 8.51 | Shares 70,000
Planned sale 13 Dec 2024
Value US$52,780.00 | Price 7.54 | Shares 7,000
Proposed sale 13 Dec 2024
Value US$52,584.00 | Price 7.51 | Shares 7,000
Sale 24 Jun 2024
Value US$54,352.00 | Price 6.32 | Shares 8,600
Proposed sale 24 Jun 2024
Value US$54,075.00 | Price 6.29 | Shares 8,600
Proposed sale 17 Jun 2024
Value US$27,994.84 | Price 5.97 | Shares 4,689
Sale 17 Jun 2024
Value US$28,134.00 | Price 6.00 | Shares 4,689
Proposed sale 14 Jun 2024
Value US$40,746.32 | Price 6.08 | Shares 6,698
Sale 14 Jun 2024
Value US$40,924.78 | Price 6.11 | Shares 6,698
Buy 30 May 2024
Value US$49,995.96 | Price 6.36 | Shares 7,861
Buy 24 May 2024
Value US$16,000.00 | Price 6.40 | Shares 2,500
Buy 20 May 2024
Value US$31,900.00 | Price 6.38 | Shares 5,000
Buy 20 May 2024
Value US$93,750.00 | Price 6.25 | Shares 15,000
Buy 20 May 2024
Value US$93,750.00 | Price 6.25 | Shares 15,000
Buy 14 May 2024
Value US$175,800.00 | Price 5.86 | Shares 30,000
Buy 14 May 2024
Value US$202,191.00 | Price 5.57 | Shares 36,300
Buy 13 May 2024
Value US$27,650.00 | Price 5.53 | Shares 5,000
Buy 13 May 2024
Value US$166,500.00 | Price 5.55 | Shares 30,000
Buy 13 May 2024
Value US$164,100.00 | Price 5.47 | Shares 30,000
Buy 13 May 2024
Value US$120,450.60 | Price 5.49 | Shares 21,940
Proposed sale 15 Jun 2023
Value US$31,779.00 | Price 7.94 | Shares 4,000
Sale 15 Jun 2023
Value US$31,920.00 | Price 7.98 | Shares 4,000
Sale 14 Jun 2023
Value US$103,442.64 | Price 8.04 | Shares 12,866
Proposed sale 14 Jun 2023
Value US$103,957.00 | Price 8.08 | Shares 12,866
Planned sale 3 Apr 2023
Value US$58,030.00 | Price 8.29 | Shares 7,000
Planned sale 1 Feb 2023
Value US$1,038,000.00 | Price 10.38 | Shares 100,000
Planned sale 15 Dec 2022
Value US$34,031.25 | Price 10.89 | Shares 3,125
Planned sale 15 Dec 2022
Value US$153,690.00 | Price 10.90 | Shares 14,100
Planned sale 15 Dec 2022
Value US$66,490.00 | Price 10.90 | Shares 6,100
Planned sale 15 Dec 2022
Value US$4,850.50 | Price 10.90 | Shares 445
Planned sale 15 Dec 2022
Value US$45,424.00 | Price 10.88 | Shares 4,175
Planned sale 15 Dec 2022
Value US$62,130.00 | Price 10.90 | Shares 5,700
Planned sale 2 Dec 2022
Value US$1,057,996.80 | Price 12.80 | Shares 82,656
Planned sale 1 Dec 2022
Value US$2,793,921.00 | Price 13.00 | Shares 214,917
Sale 1 Dec 2022
Value US$111,886.00 | Price 13.01 | Shares 8,600
Sale 14 Nov 2022
Value US$437,428.20 | Price 13.88 | Shares 31,515
Planned sale 18 Apr 2022
Value US$55,200.00 | Price 11.04 | Shares 5,000
Planned sale 1 Apr 2022
Value US$123,120.00 | Price 16.20 | Shares 7,600
Sale 10 Mar 2022
Value US$24,696.00 | Price 17.64 | Shares 1,400
Sale 10 Mar 2022
Value US$2,694,796.93 | Price 16.87 | Shares 159,739
Sale 7 Mar 2022
Value US$343,200.00 | Price 17.16 | Shares 20,000
Sale 1 Mar 2022
Value US$39,560.00 | Price 17.20 | Shares 2,300
Planned sale 15 Feb 2022
Value US$92,500.00 | Price 18.50 | Shares 5,000
Planned sale 11 Jan 2022
Value US$2,767,360.00 | Price 15.04 | Shares 184,000
Sale 7 Dec 2021
Value US$367,220.00 | Price 12.20 | Shares 30,100
Buy 24 Nov 2021
Value US$91,425.00 | Price 12.19 | Shares 7,500
Buy 23 Nov 2021
Value US$440,019.84 | Price 12.48 | Shares 35,258
Planned sale 15 Nov 2021
Value US$61,350.00 | Price 12.27 | Shares 5,000
Planned sale 15 Oct 2021
Value US$1,617,000.00 | Price 15.40 | Shares 105,000
Planned sale 15 Sep 2021
Value US$75,300.00 | Price 15.06 | Shares 5,000
Sale 10 Sep 2021
Value US$1,116,660.00 | Price 15.09 | Shares 74,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-18 S Sale
0.6
McKee Amy E
Non-Executive Director
35,624 -28.7%
216.39
US$330,810 		35,624 -28.7% 216.39 US$330,810
2026-05-18 2026-05-18 PrS Proposed sale
0.6
Amy McKee

Director

Non-Executive Director
86,543
90.58
US$2,330,268 		86,543 90.58 US$2,330,268
2026-05-15 2026-05-13 PlS Planned sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
22,254 -49.5%
94.58
US$4,958,567 		22,254 -49.5% 94.58 US$4,958,567
2026-05-13 2026-05-13 PrS Proposed sale
2.0
Barnes Alane P

Officer

Officer
62,500
9.54
US$596,250 		62,500 9.54 US$596,250
2026-03-24 2026-03-20 S Sale
3.3
HEGGIE THERESA
Non-Executive Director
49,933 -43.3%
10.11
US$504,823 		49,933 -43.3% 10.11 US$504,823
2026-03-20 2026-03-20 PrS Proposed sale
3.3
HEGGIE THERESA

Director

Non-Executive Director
49,933
10.11
US$504,620 		49,933 10.11 US$504,620
2026-03-18 2026-03-16 PlS Planned sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
150,000 -27.2%
9.15
US$1,372,500 		150,000 -27.2% 9.15 US$1,372,500
2026-03-16 2026-03-16 PrS Proposed sale
2.0
Barnes Alane P

Officer

Officer
150,000
9.15
US$1,372,007 		150,000 9.15 US$1,372,007
2026-03-02 2026-03-02 PrS Proposed sale
3.3
Stonehouse Jon P

Director

Non-Executive Director
305,995
8.65
US$2,646,857 		305,995 8.65 US$2,646,857
2025-12-23 2025-12-22 PlS Planned sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
21,773 -5.2%
7.65
US$166,563 		21,773 -5.2% 7.65 US$166,563
2025-12-22 2025-12-22 PrS Proposed sale
2.0
Barnes Alane P

Officer

Officer
21,773
7.65
US$166,563 		21,773 7.65 US$166,563
2025-12-16 2025-12-15 PlS Planned sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
21,210 -6.3%
7.65
US$162,256 		21,210 -6.3% 7.65 US$162,256
2025-12-15 2025-12-15 PrS Proposed sale
2.0
Barnes Alane P

Officer

Officer
21,210
7.65
US$162,256 		21,210 7.65 US$162,256
2025-12-03 2025-12-03 PrS Proposed sale
2.0
Barnes Alane P

Officer

Officer
19,770
7.65
US$151,240 		19,770 7.65 US$151,240
2025-12-03 2025-12-03 PlS Planned sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
19,770 -5.4%
7.65
US$151,240 		19,770 -5.4% 7.65 US$151,240
2025-12-03 2025-12-02 S Sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
50,906 -12.2%
7.21
US$367,216 		50,906 -12.2% 7.21 US$367,216
2025-12-02 2025-12-02 PrS Proposed sale
2.0
Barnes Alane P

Officer

Officer
50,906
7.21
US$367,216 		50,906 7.21 US$367,216
2025-12-03 2025-12-01 PlS Planned sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
91,004 -17.9%
7.10
US$646,511 		91,004 -17.9% 7.10 US$646,511
2025-12-01 2025-12-01 PrS Proposed sale
2.0
Barnes Alane P

Officer

Officer
91,004
7.08
US$644,308 		91,004 7.08 US$644,308
2025-11-25 2025-11-25 PrS Proposed sale
3.6
Helen M Thackray

Officer

Officer
48,229
6.80
US$327,957 		48,229 6.80 US$327,957
2025-11-21 2025-11-21 PrS Proposed sale
3.6
Helen Thackray

Officer

Officer
43,275
7.11
US$307,685 		43,275 7.11 US$307,685
2025-11-17 2025-11-13 PlS Planned sale
2.2
SANDERS MACHELLE
Non-Executive Director
9,600 -23.9%
7.14
US$68,544 		9,600 -23.9% 7.14 US$68,544
2025-11-13 2025-11-13 PrS Proposed sale
2.2
SANDERS MACHELLE

Officer

Officer
9,600
7.14
US$68,544 		9,600 7.14 US$68,544
2025-08-15 2025-08-13 S Sale
3.3
HEGGIE THERESA
Non-Executive Director
70,000 -51.7%
8.51
US$595,868 		70,000 -51.7% 8.51 US$595,868
2025-08-13 2025-08-13 PrS Proposed sale
3.3
HEGGIE THERESA

Director

Non-Executive Director
70,000
8.51
US$595,871 		70,000 8.51 US$595,871
2024-12-16 2024-12-13 PlS Planned sale
3.7
Hutson Nancy J
Non-Executive Director
7,000 -7.5%
7.54
US$52,780 		7,000 -7.5% 7.54 US$52,780
2024-12-13 2024-12-13 PrS Proposed sale
3.7
Hutson Nancy J

Director

Non-Executive Director
7,000
7.51
US$52,584 		7,000 7.51 US$52,584
2024-06-25 2024-06-24 S Sale
0.6
McKee Amy E
Non-Executive Director
8,600 -23.6%
6.32
US$54,352 		8,600 -23.6% 6.32 US$54,352
2024-06-24 2024-06-24 PrS Proposed sale
0.6
McKee Amy E

Director

Non-Executive Director
8,600
6.29
US$54,075 		8,600 6.29 US$54,075
2024-06-17 2024-06-17 PrS Proposed sale
2.2
SANDERS MACHELLE

Director

Non-Executive Director
4,689
5.97
US$27,995 		4,689 5.97 US$27,995
2024-06-17 2024-06-17 S Sale
2.2
SANDERS MACHELLE
Non-Executive Director
4,689 -14.5%
6.00
US$28,134 		4,689 -14.5% 6.00 US$28,134
2024-06-14 2024-06-14 PrS Proposed sale
3.3
HEGGIE THERESA

Director

Non-Executive Director
6,698
6.08
US$40,746 		6,698 6.08 US$40,746
2024-06-14 2024-06-14 S Sale
3.3
HEGGIE THERESA
Non-Executive Director
6,698 -11.2%
6.11
US$40,925 		6,698 -11.2% 6.11 US$40,925
2024-05-31 2024-05-30 B Purchase
3.1
LEVIN ALAN G
Non-Executive Director
7,861 +21.2%
6.36
US$49,996 		7,861 +21.2% 6.36 US$49,996
2024-05-29 2024-05-24 B Purchase
3.4
ASELAGE STEVE
Non-Executive Director
2,500 +inf%
6.40
US$16,000 		2,500 +inf% 6.40 US$16,000
2024-05-22 2024-05-20 B Purchase
3.7
Hutson Nancy J
Non-Executive Director
5,000 +6.1%
6.38
US$31,900 		5,000 +6.1% 6.38 US$31,900
2024-05-22 2024-05-20 B Purchase
3.4
MILANO VINCENT
Non-Executive Director
15,000 +28.8%
6.25
US$93,750 		15,000 +28.8% 6.25 US$93,750
2024-05-22 2024-05-20 B Purchase
3.4
MILANO VINCENT
Non-Executive Director
15,000 +28.8%
6.25
US$93,750 		15,000 +28.8% 6.25 US$93,750
2024-05-15 2024-05-14 B Purchase
3.6
Thackray Helen M.

Chief R&D Officer

Officer
30,000 +12.4%
5.86
US$175,800 		30,000 +12.4% 5.86 US$175,800
2024-05-15 2024-05-14 B Purchase
3.7
Doyle Anthony

Chief Financial Officer

Officer
36,300 +15.8%
5.57
US$202,191 		36,300 +15.8% 5.57 US$202,191
2024-05-15 2024-05-13 B Purchase
2.0
Barnes Alane P

Chief Legal Officer

Officer
5,000 +1.7%
5.53
US$27,650 		5,000 +1.7% 5.53 US$27,650
2024-05-15 2024-05-13 B Purchase
3.3
Stonehouse Jon P

President & CEO

Executive Director
30,000 +2.7%
5.55
US$166,500 		30,000 +2.7% 5.55 US$166,500
2024-05-15 2024-05-13 B Purchase
3.3
Gayer Charles K

Chief Commercial Officer

Officer
30,000 +10.8%
5.47
US$164,100 		30,000 +10.8% 5.47 US$164,100
2024-05-15 2024-05-13 B Purchase
3.3
Galson Steven K
Non-Executive Director
21,940 +74.1%
5.49
US$120,451 		21,940 +74.1% 5.49 US$120,451
2023-06-15 2023-06-15 PrS Proposed sale
2.2
SANDERS MACHELLE

Officer

Officer
4,000
7.94
US$31,779 		4,000 7.94 US$31,779
2023-06-15 2023-06-15 S Sale
2.2
SANDERS MACHELLE
Non-Executive Director
4,000 -13.5%
7.98
US$31,920 		4,000 -13.5% 7.98 US$31,920
2023-06-15 2023-06-14 S Sale
3.7
Hutson Nancy J
Non-Executive Director
12,866 -13.6%
8.04
US$103,443 		12,866 -13.6% 8.04 US$103,443
2023-06-14 2023-06-14 PrS Proposed sale
3.7
Hutson Nancy J

Officer

Officer
12,866
8.08
US$103,957 		12,866 8.08 US$103,957
2023-04-05 2023-04-03 PlS Planned sale
3.6
Thackray Helen M.

Chief R&D Officer

Officer
7,000 -3.3%
8.29
US$58,030 		7,000 -3.3% 8.29 US$58,030
2023-02-02 2023-02-01 PlS Planned sale
3.3
Stonehouse Jon P

President & CEO

Executive Director
100,000 -9.0%
10.38
US$1,038,000 		100,000 -9.0% 10.38 US$1,038,000
2022-12-19 2022-12-15 PlS Planned sale
3.6
Thackray Helen M.

Chief R&D Officer

Officer
3,125 -2.3%
10.89
US$34,031 		3,125 -2.3% 10.89 US$34,031
2022-12-19 2022-12-15 PlS Planned sale
3.3
Stonehouse Jon P

President & CEO

Executive Director
14,100 -1.6%
10.90
US$153,690 		14,100 -1.6% 10.90 US$153,690
2022-12-19 2022-12-15 PlS Planned sale
3.3
Gayer Charles K

Chief Commercial Officer

Officer
6,100 -2.8%
10.90
US$66,490 		6,100 -2.8% 10.90 US$66,490
2022-12-19 2022-12-15 PlS Planned sale
3.7
Jones Michael L

Exec. Director, Finance - PAO

Officer
445 -4.0%
10.90
US$4,850 		445 -4.0% 10.90 US$4,850
2022-12-19 2022-12-15 PlS Planned sale
2.0
Barnes Alane P

Chief Legal Officer

Officer
4,175 -2.1%
10.88
US$45,424 		4,175 -2.1% 10.88 US$45,424
2022-12-19 2022-12-15 PlS Planned sale
3.7
Doyle Anthony

Chief Financial Officer

Officer
5,700 -3.4%
10.90
US$62,130 		5,700 -3.4% 10.90 US$62,130
2022-12-02 2022-12-02 PlS Planned sale
3.3
Stonehouse Jon P

President & CEO

Executive Director
82,656 -8.4%
12.80
US$1,057,997 		82,656 -8.4% 12.80 US$1,057,997
2022-12-02 2022-12-01 PlS Planned sale
3.3
Stonehouse Jon P

President & CEO

Executive Director
214,917 -19.2%
13.00
US$2,793,921 		214,917 -19.2% 13.00 US$2,793,921
2022-12-02 2022-12-01 S Sale
3.7
Jones Michael L

Exec. Director, Finance - PAO

Officer
8,600 -43.4%
13.01
US$111,886 		8,600 -43.4% 13.01 US$111,886
2022-11-16 2022-11-14 S Sale
3.3
Babu Yarlagadda S

Chief Discovery Officer

Officer
31,515 -9.5%
13.88
US$437,428 		31,515 -9.5% 13.88 US$437,428
2022-04-20 2022-04-18 PlS Planned sale
2.9
ABERCROMBIE GEORGE B
Non-Executive Director
5,000 -100.0%
11.04
US$55,200 		5,000 -100.0% 11.04 US$55,200
2022-04-04 2022-04-01 PlS Planned sale
3.6
Thackray Helen M.

Chief R&D Officer

Officer
7,600 -5.3%
16.20
US$123,120 		7,600 -5.3% 16.20 US$123,120
2022-03-14 2022-03-10 S Sale
3.3
Sheridan William P

Chief Medical Officer

Officer
1,400 -3.6%
17.64
US$24,696 		1,400 -3.6% 17.64 US$24,696
2022-03-14 2022-03-10 S Sale
3.3
Sheridan William P

Chief Medical Officer

Officer
159,739 -80.2%
16.87
US$2,694,797 		159,739 -80.2% 16.87 US$2,694,797
2022-03-09 2022-03-07 S Sale
3.3
Babu Yarlagadda S

Chief Discovery Officer

Officer
20,000 -8.0%
17.16
US$343,200 		20,000 -8.0% 17.16 US$343,200
2022-03-03 2022-03-01 S Sale
3.7
Jones Michael L

Exec. Director, Finance - PAO

Officer
2,300 -17.0%
17.20
US$39,560 		2,300 -17.0% 17.20 US$39,560
2022-02-16 2022-02-15 PlS Planned sale
2.9
ABERCROMBIE GEORGE B
Non-Executive Director
5,000 -100.0%
18.50
US$92,500 		5,000 -100.0% 18.50 US$92,500
2022-01-13 2022-01-11 PlS Planned sale
3.3
Stonehouse Jon P

President & CEO

Executive Director
184,000 -16.9%
15.04
US$2,767,360 		184,000 -16.9% 15.04 US$2,767,360
2021-12-09 2021-12-07 S Sale
3.3
Babu Yarlagadda S

Chief Discovery Officer

Officer
30,100 -12.3%
12.20
US$367,220 		30,100 -12.3% 12.20 US$367,220
2021-11-24 2021-11-24 B Purchase
3.4
MILANO VINCENT
Non-Executive Director
7,500 +75.0%
12.19
US$91,425 		7,500 +75.0% 12.19 US$91,425
2021-11-24 2021-11-23 B Purchase
3.7
Doyle Anthony

Chief Financial Officer

Officer
35,258 +60.3%
12.48
US$440,020 		35,258 +60.3% 12.48 US$440,020
2021-11-17 2021-11-15 PlS Planned sale
2.9
ABERCROMBIE GEORGE B
Non-Executive Director
5,000 -100.0%
12.27
US$61,350 		5,000 -100.0% 12.27 US$61,350
2021-10-19 2021-10-15 PlS Planned sale
3.7
Hutson Nancy J
Non-Executive Director
105,000 -61.7%
15.40
US$1,617,000 		105,000 -61.7% 15.40 US$1,617,000
2021-09-17 2021-09-15 PlS Planned sale
2.9
ABERCROMBIE GEORGE B
Non-Executive Director
5,000 -100.0%
15.06
US$75,300 		5,000 -100.0% 15.06 US$75,300
2021-09-14 2021-09-10 S Sale
2.9
ABERCROMBIE GEORGE B
Non-Executive Director
74,000 -100.0%
15.09
US$1,116,660 		74,000 -100.0% 15.09 US$1,116,660
Explore more

More insider trading research around BioCryst Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America